- Home
- RYOJ vs EDSA Comparison
RYOJ vs EDSA Comparison
Compare RYOJ & EDSA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | RYOJ | EDSA |
|---|---|---|
| Founded | 2015 | 2015 |
| Country | Japan | Canada |
| Employees | N/A | N/A |
| Industry | Professional Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 56.9M | 51.5M |
| IPO Year | 2024 | 2018 |
Fundamental Metrics
Financial Performance| Metric | RYOJ | EDSA |
|---|---|---|
| Price | $2.74 | $3.58 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $16.33 |
| AVG Volume (30 Days) | 11.0K | ★ 34.3K |
| Earning Date | 03-23-2026 | 08-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $19.04 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $1.56 | $0.72 |
| 52 Week High | $11.43 | $20.32 |
Technical Indicators
Market Signals| Indicator | RYOJ | EDSA |
|---|---|---|
| Relative Strength Index (RSI) | 33.25 | 36.23 |
| Support Level | $2.84 | $3.47 |
| Resistance Level | $2.95 | $4.27 |
| Average True Range (ATR) | 0.31 | 0.29 |
| MACD | -0.06 | 0.01 |
| Stochastic Oscillator | 15.72 | 7.51 |
Price Performance
Historical ComparisonAbout RYOJ rYojbaba Co. Ltd.
rYojbaba Co Ltd is engaged in improving and restoring physical and mental health diminished by work-related stress through consulting and health services. The company provides consulting services to labor unions and companies wishing to build constructive relationships with labor unions and health services to osteopathic clinics and osteopathic beauty salons to alleviate physical ailments created by work-related stress.
About EDSA Edesa Biotech Inc.
Edesa Biotech Inc is a biotechnology company focused on inflammatory and immune-related diseases. It is involved in exploring novel ways to treat these diseases, including alternatives to topical steroids, which can have side effects. The company's product candidate, EB06, is an anti-CXCL10 monoclonal antibody candidate and is being developed as a therapy for vitiligo, a common autoimmune disorder that causes the skin to lose its color in patches. The other drug candidates in its product pipeline include EB05, EB07, and EB01 which are in their different phases of development.